Base Therapeutics and Synthego Forge Global Partnership to Commercialize AccuBase® Base Editing Proteins, Pioneering a New Era in Gene Editing
Synthego
Gene Engineering Solutions Provider
Introduction:
Gene Editing Technology Reaches Another Milestone! Base Therapeutics Partners with Global Leader Synthego in Strategic Collaboration; Synthego to Officially Distribute AccuBase Developed by Base Therapeutics®Base Editing Proteins (Research Grade and GMP Grade). This collaboration is a deepening of the tripartite agreement between Base Therapeutics, Kactus Biosystems, and Synthego, aiming to accelerate AccuBase through global channels.®The application of technology provides safer and more efficient gene editing solutions for basic research and the biopharmaceutical field!
Gene Editing 2.0 Era: AccuBase®Breakthrough Advantages
Traditional CRISPR gene editing technologies, such as Cas9 and Cas12, rely on DNA double-strand breaks, posing risks like chromosome loss and chromosomal translocation, whereas AccuBase®Base editing proteins, as representatives of CRISPR 2.0 technology, have become the "new favorite" in scientific research and clinical applications due to the following advantages:
Zero-Risk Editing: Without causing double-strand breaks, avoiding chromosomal translocations or losses;
Ultra-high precision: The editing results are predictable, without sgRNA-independent off-target effects;
Cell-Friendly: No impact on p53, multi-site editing still maintains cell stability;
The Only One in the World: Currently the only GMP-grade base editing protein, meeting clinical-grade requirements.
“AccuBase®"The birth marks the transition of gene editing from 'cutting' to a new phase of 'precise modification.'"
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Tripartite Collaboration: Global Layout, Empowering Research and Healthcare
Why Choose AccuBase®？
Basic Research: Provide scholars with safer tools to explore complex gene functions;
Drug Development: GMP-grade proteins can be directly used in cell therapy products, accelerating clinical trials;
Patent Protection: The technology has clear intellectual property through FTO analysis.
Looking Ahead
Base Therapeutics Founder and CEO Tianhong Xu stated: "The collaboration with Synthego is AccuBase®"An important step in globalization. We look forward to working with more partners to make gene editing technology truly benefit human health."
About Synthego and Kactus Biosystems
Synthego: A global leading supplier of life science solutions.Synthego is a global leading provider of gene editing solutions, headquartered in California, USA, and established in 2012. The company focuses on CRISPR technology, offering high-throughput sgRNA synthesis, gene editing kits, and an AI-driven design platform, serving the research and pharmaceutical fields. Its CRISPRevolution®The system is widely used by top laboratories worldwide and is known for its high precision and automation. Synthego collaborates with companies like Base Therapeutics to promote the application of cutting-edge technologies such as base editing, accelerating the development of gene therapy.
Kactus BiosystemsKactus Biosystem is an innovative biotechnology company specializing in recombinant protein and enzyme products. Headquartered in Shanghai, with branches in North America and Europe. Leveraging advanced protein expression and purification platforms, it is committed to providing high-quality raw materials for gene editing, cell therapy, and biopharmaceutical fields, including GMP-grade proteins and CRISPR-related enzyme products. As an important partner of Base Therapeutics, Kactus Biosystem is responsible for producing AccuBase.®Base Editing Proteins, Empowering Global Research and Clinical Studies. With rigorous processes and a stable supply chain, Kactus Biosystems has provided multiple GMP enzymes that meet drug submission standards to customers both in China and internationally, establishing itself as a raw enzyme supplier of international caliber.
Base Therapeutics
Founded in 2021, Base Therapeutics is a high-tech enterprise and science-oriented small and medium-sized business that focuses on fundamental innovations in gene editing. It is a global leader in the fields of base editing and cell-based gene therapies. We are committed to developing internationally pioneering cell therapy and gene editing products, which show great potential, especially in the treatment of cancer and genetic diseases.
Base Therapeutics has a GMP cell production facility of nearly 2,500 square meters and a laboratory of 1,500 square meters to meet the stringent requirements for the research and production of clinical-grade cell therapy products. In addition to NK510 and NK520, Base Therapeutics' product pipeline also includes CAR-T products based on base editing and in vivo base editing products.
Meanwhile, Base Therapeutics has cumulatively received tens of millions of dollars in seed and Series A funding, with strong venture capital backing, supported by world-class biopharmaceutical venture capital institutions. We have been honored with multiple awards, including the second prize in the 12th China Innovation and Entrepreneurship Competition National Finals, first place in the Yangtze River Delta JuJin Science and Technology Innovation Competition, second prize in the High-Value Patent Operation Competition, as well as recognition in the "Chuangling Pudong" Innovation and Entrepreneurship Competition and the "Haichuang Competition." Additionally, we hold 30 patents both in China and internationally.
Looking ahead, Base Therapeutics will strive to become a global leader in the gene editing field through continuous technological innovation and product development, driving industry progress and bringing revolutionary treatment solutions to patients worldwide.
Base Therapeutics' base-edited NK cell therapy has entered clinical research in some tertiary hospitals in the Yangtze River Delta region, aiming to explore the efficacy and safety in treating various solid tumors and hematologic malignancies that are recurrent, refractory, or metastatic after failed conventional chemotherapy, including solid tumors and autoimmune diseases. Currently, patient enrollment for each research project is actively underway.
Part of WinX Capital's Successful Transactions
Biopharmaceuticals:SynthegoTongrui BioCanSino BiologicsHaiChuang PharmaGreen Bamboo BiotechSyntheco PharmaceuticalsXuanzhu BioHuiSheng BioAidu BioVivaVision BioJinlan GeneQureBioChangxi PharmaQingpu BioHoyuncellSuikun IntelligenceNovobiomRed Cloud BioComplife BiotechTianchen BiotechBioShineZedmanQuality Peptide BioEnze TaikangArthur PharmaceuticalsYoujia BioSynthCell BiotechBoin BiotechChina Cause TechnologyPurigin BioSynthBioHuaten PharmaceuticalBioinnoWuJiaHe Gene
Biomanufacturing&Agrifood Technology：Junhe AllianceMethuselahSynthegoLipho BiotechSynthgeneMeibai BioBaiKuiRui BioRongrui TechnologyDermaVita TechHuahao ZhongtianBoruideQiheshengkeGreenonDingchi BioHuapai BiotechBlue Beauty Co., Ltd.Aidijing